

# Transurethral Resections of Bladder Diagnostic Pitfalls and Mimickers

George J. Netto, M.D.

Professor and Chair of Pathology

**University of Alabama at Birmingham** 

#### **Mimickers of Bladder Carcinoma**

#### Mimickers of Bladder Carcinoma

- Benign Mimickers of Urothelial Carcinoma
- Benign Mimickers of Bladder Adenocarcinoma

- Malignant Mimickers of Urothelial Carcinoma
- Malignant Mimickers of Bladder Adenocarcinoma

# Benign Mimickers of Urothelial Ca

- Reactive urothelial atypia
- Polypoid/Papillary Cystitis
- X-Ray Rx/Chemo Rx Induced Changes
  - Radiation Atypia
  - Intravesical ChemoRx
  - Systemic ChemoRx: Cytoxan
  - Pseudocarcinomatous Hyperplasia

# Benign Mimickers of Urothelial Ca

- Reactive urothelial atypia
- Polypoid/Papillary Cystitis
- X-Ray Rx/Chemo Rx Induced Changes
  - Radiation Atypia
  - Intravesical Rx
  - Systemic ChemoRx: Cytoxan
  - Pseudocarcinomatous Hyperplasia


# **Polypoid/Papillary Cystitis**


- Reaction to injury
- Indwelling catheters, fistula, abscess, long-standing urinary obstruction
- Often recognized as inflammatory by urologist at cystoscopy: bullous, polypoid, papillary


# **Polypoid/Papillary Cystitis**


#### Lane, Z et al. Am J Surg Pathol 2008


- 41/ 155 cases misdiagnosed as UrCa (2000-2007)
- Prior Hx: Stent, radiation Rx, fistula etc...
- The key to Dx is low magnification impression of reactive lesion
- Inflamed background: edematous or densely fibrous
- Predominantly simple, non-branching, broad-based fronds
- Relatively normal thickness urothelium
- ? polypoid cystitis 
   ⇒ clinical history and cystoscopy impression that might suggest a reactive process.



















# Benign Mimickers of Urothelial Ca


- Reactive urothelial atypia
- Polypoid/Papillary Cystitis
- X-Ray Rx/Chemo Rx Induced Changes
  - Radiation Atypia
  - Intravesical Rx
  - Systemic ChemoRx: Cytoxan
  - Pseudocarcinomatous Hyperplasia


# Radiotherapy Induced Urothelial Atypia


- Urothelial cell enlargement, multinucleation, and smudgy/degenerative.
   chromatin pattern vacuolization with maintenance of abundant cytoplasm.
- Just because there is urothelial atypia with a history of radiotherapy, one cannot discount the possibility of CIS, as radiation is also associated with an increased risk of bladder cancer. Mitotic figures are more consistent with CIS.
- Atypia persisting over 12 months following radiation? R/O neoplastic lesion











#### Pseudocarcinomatous Hyperplasia of Bladder

- Less familiar to pathologists is "radiation-induced pseudocarcinomatous hyperplasia".
- Baker and Young in 2000: first series (4 pts) to report this benign mimicker of invasive urothelial carcinoma.

#### Pseudocarcinomatous Hyperplasia

#### Chan, T. et al. Am J Surg Pathol 2004

- 20 bladder cases; either radiation or chemotherapy induced
- All 17 cases where follow-up available had benign clinical course
- All patients presented with hematuria
- Pts: 80% male; mean age 69.
- The mean interval from radiation 27 months. longest 79 months.

#### **Prior Therapy?**

#### Chan et al. Am J surg Pathol 2004

Pelvic irradiation
 15 Prostate cancer

2 Endometrial cancer


Systemic chemotherapy 1 Metastatic colon cancer


1 Mixed connective tissue Dz


Unknown
 1 Laryngeal cancer.


#### Lane, Z et al. Am J Surg Pathol 2008


- All 8 cases without prior X-Ray or ChemoRx
- Atrial fibrilation, hypertentsion, hyperlipidemia, AVM of bladder, Recent GI bleeding, UB catheterization





















# **Histologic Clues to Benign Nature**


- Edema (94%), vascular congestion (78%), hemosiderin (56%)
- Most importantly fibrin deposits with urothelial nests encircling the fibrin
- Nests do not extend irregularly down into the lamina propria or muscularis propria as is seen with the urothelial carcinoma
- Ulceration (39%) and thickened vessels (72%), which are clues to the prior irradiation


### Benign Mimickers of Bladder Adenocarcinoma

- Florid cystitis cystica et glandularis
- Endocervicosis/mullarianosis
- Nephrogenic adenoma (Nephrogenic metaplasia)












CCG with high grade glandular dysplasia!


# Benign Mimickers of Bladder Adenocarcinoma


- Florid cystitis cystica et glandularis
- Endocervicosis/mullarianosis
- Nephrogenic adenoma (Nephrogenic metaplasia)

















Bladder adenocarcinoma NOS!


# Benign Mimickers of Bladder Adenocarcinoma


- Florid cystitis cystica et glandularis
- Endocervicosis/mullarianosis
- Nephrogenic adenoma (Nephrogenic metaplasia)





























# Malignant Mimickers of Bladder Carcinoma

### Malignant Mimickers of Urothelial Carcinoma


- PCa (Gleason 5)
- Pheochromocytoma


## Malignant Mimickers of Adenocarcinoma


- CRCa
- PCa (Gleason 3,4)
- Other metastatic adenocarcinoma

### Case 1

A 58 yr old male smoker presented with persistent microhematuria; a TURB was performed.







## **Case # 1**

### Diagnosis:

- A. Invasive Urothelial Carcinoma, High Grade
- B. Malignant Melanoma
- C. Paraganglioma
- D. Large Cell Neuroendocrine Carcinoma

### **Case # 1**

## Diagnosis:

- A. Invasive Urothelial Carcinoma, High Grade
- B. Malignant Melanoma
- C. Paraganglioma
  - D. Large Cell Neuroendocrine Carcinoma

## **Paraganglioma**

### Clinical Characteristics

### Clinical Features

- Rare bladder tumor (<1%); middle aged women</li>
- Classic presentation
  - paroxysmal hypertension
  - micturition attacks (headache, palpitations, diaphoresis, blurred vision)
- Cystoscopy
  - "submucosal" mass

## **Biologic Behavior**

- 5-15% malignant behavior
- No reliable criteria to accurately predict

### **Paraganglioma**


### Immunohistochemistry & Molecular Dx


#### IHC:


- Chromogranin (+), synaptophysin (+), S100 (+) sustentacular
- Cytokeratins (AE1/AE3, CK903, CK7, CK20): usually (-)
- p63 (-)
- GATA3 POSITIVE!


#### **Molecular Dx:**


- MEN2: RET
- von Hippel-Lindau disease: vHL
- Neurofibromatosis 1 (NF 1)
- Paraganglioma syndromes type 1,3,4: SDH subunits D, C, B

















SYN

S100

## **Paraganglioma**

### **Histologic Clues:**

- Rich vascular pattern
- Nested architechture
- Large polygonal cells with abundant amphophilic granular cytoplasm


#### DDX:

- Cautery artifact & infiltration of detrusor muscle 

  misinterpretation as URCa
- Significant clinical implications

### Case 2

A 59 yr old female smoker presented with gross hematuria; a TURB was performed.



### **Case # 2**


### Diagnosis:

- A. Villous Adenoma with Associated Invasive Adenocarcinoma of Urinary Bladder
- B. Secondary bladder involvement by Colonic Adenocarcinoma
- C. Urachal Adenocarcinoma
- D. Cystitis Cystica et Glandularis.


# **Case # 2**

# Diagnosis:


- A. Villous Adenoma with Invasive Adenocarcinoma of Urinary Bladder
- B. Secondary bladder involvement by Colonic Adenocarcinoma
- C. Urachal Adenocarcinoma
- D. Cystitis Cystica et Glandularis.




Bladder Adenocarcinoma, Intestinal type




Bladder Adenocarcinoma, Intestinal type




Bladder Adenocarcinoma, Intestinal type



Bladder Adenocarcinoma, Intestinal type



Bladder Adenocarcinoma, Intestinal type



Bladder Adenocarcinoma, Signet Ring Mucinous

# **Secondary Tumors of Urinary Bladder**

#### **CRCa vs Primary Adenocarcinoma**

- Secondary CRCa spread to bladder is more common occurrence
- Differentiating a CRCa spread from "intestinal type" primary can not be made with absolute certainty
- Presence of a background of intestinal metaplasia/villoglandular adenomatous dysplasia can be mimicked by colonization by secondary well differentiated CRCa
- A recommendation to rule out spread should be forwarded to avoid a potentially unjustifiable radical cystectomy

# **Secondary Tumors of Urinary Bladder**

#### **CRCa Vs Primary Bladder Adenocarcinoma**

- Wang HL et al. AJSP 2001
   Nuclear B-catenin (-), CK7(+) 65%, CK20(+) 50%
- Suh N et al. Mod Pathol 2005
   CDX2 (+) 50% and Villin (+) 60%
- Raspollini MR et al. appl immunohistochem mol morphol 2005
   CDX2 (+) 13%, CK7 (+) 60%, CK20 (+) 60%


IHC
CRCa Spread Vs Primary Bladder Adenocarcinoma

| MARKER            | Primary Bladder<br>Adenocarcinoma | CRCa<br>spread to Bladder |
|-------------------|-----------------------------------|---------------------------|
| CDX2              | + (15-50%)                        | + (100%)                  |
| Nuclear B Catenin | -                                 | + (80%)                   |
| Ck 20             | + (50-60%)                        | + (95%)                   |
| СК7               | + (60%)                           | + (5%)                    |
| Villin            | + (60%)                           | + (98%)                   |
| GATA3             | +/-                               | -                         |


Wang HL et al. AJSP 2001; Raspollini MR et al. appl immuno 2005; Suh N et al. Mod Pathol 2005


# **Secondary Tumors of Urinary Bladder**

- Most common sources: colorectal (33%), prostatic (12%) and cervical (11%) sites
- Other sources include breast, stomach, lung and melanoma primaries.



Metastatic Pancreatic Ductal Adenocarcinoma





Prostate Adenocarcinoma

### **CONCLUSIONS**

- Bladder cancer mimickers include benign entities as well as malignancies
- Extension or Metastases from extravesical primaries should be considered when a CIS or Non-Invasive Papillary precursor is not identifiable





